Related Experiment Video
Updated: Nov 16, 2025
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Systemic Options for Malignant Peripheral Nerve Sheath Tumors
Ayesha Hassan1,2, Roberto Carmagnani Pestana3, Amanda Parkes4,5
1Department of Medicine, Division of Hematology, Medical Oncology, and Palliative Care, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Opinion Statement:
Malignant peripheral nerve sheath tumors (MPNSTs) are rare mesenchymal neoplasms that represent a profound therapeutic challenge due to their high proclivity for recurrence and metastasis and relatively poor response to systemic therapy regimens. While our understanding of the pathophysiology of MPNST is growing, including loss of the tumor suppressor gene neurofibromin and subsequent activation of the Ras pathway, targeted therapy to modify the poor prognosis seen in MPNST patients has thus far been without success. Correspondingly, MPNST patients are treated as per soft tissue sarcoma treatment algorithms with anthracycline-based therapy as the front-line therapy of choice for patients with unresectable, locally advanced, or metastatic MPNST. Beyond first-line anthracycline-based therapy, other standard cytotoxic chemotherapy agents used in advanced MPNST include the alkylating agent ifosfamide and the topoisomerase II inhibitor etoposide. Notably, soft tissue sarcoma regimens are used in MPNST despite distinct systemic therapy sensitivity and prognosis. This is particularly notable for neurofibromatosis type 1 (NF1)-associated MPNST, which is associated with poorer response to systemic therapy and prognosis than sporadic MPNST. As such, NF1-associated MPNST is a particular area in need of novel therapeutic strategies. Given the lack of benefit in the targeting of unique aspects of MPNST disease biology thus far, pre-clinical studies to identify novel rational therapies are critical to inform future clinical trials.
Insights
Malignant peripheral nerve sheath tumors (MPNSTs) are challenging to treat, often recurring and metastasizing. Current therapies, based on soft tissue sarcoma treatments, show limited success, especially for neurofibromatosis type 1 (NF1)-associated MPNST, highlighting the need for new strategies.
Area of Science:
- Oncology
- Cancer Biology
- Genetics
Background:
- Malignant peripheral nerve sheath tumors (MPNSTs) are rare, aggressive cancers with high recurrence and metastasis rates.
- Current treatment strategies for MPNSTs are largely based on soft tissue sarcoma protocols, yielding suboptimal outcomes.
- The pathophysiology involves neurofibromin loss and Ras pathway activation, yet targeted therapies have been unsuccessful.
Purpose of the Study:
- To review the current therapeutic landscape for MPNSTs.
- To highlight the limitations of existing treatments, particularly for neurofibromatosis type 1 (NF1)-associated MPNST.
- To emphasize the critical need for novel therapeutic strategies informed by preclinical research.
Main Methods:
- Literature review of MPNST pathophysiology and treatment responses.
- Analysis of current clinical practices and systemic therapy regimens.
- Evaluation of the efficacy of standard chemotherapy agents like anthracyclines, ifosfamide, and etoposide.
Main Results:
- MPNSTs exhibit poor response to conventional systemic therapies, including anthracycline-based regimens.
- Neurofibromatosis type 1 (NF1)-associated MPNST shows a worse prognosis and reduced response to therapy compared to sporadic MPNST.
- Existing treatments do not adequately address the unique biology of MPNST, leading to limited clinical benefit.
Conclusions:
- Novel therapeutic strategies are urgently required for MPNST, especially for NF1-associated cases.
- Preclinical studies are essential to identify and validate new therapeutic targets and agents.
- Future clinical trials must be informed by a deeper understanding of MPNST biology to improve patient outcomes.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
03:53Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management
Published on: March 15, 2024